The results showed that immune, stromal, and ESTIMATE scores in the high-LOX-expression group were remarkably higher compared to the low-LOX-expression group in TCGA (Figures 5A–C) and GSE84437 (Figures 5D–F) databases, which supports our guess that the overexpression of LOX indeed modifies the tumor microenvironment in gastric cancer. This evidence concerns the gene LOX and gastric cancer.